Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience

“…At presentation, some patients had limited metastatic disease, called oligometastases, confined to 1 or 2 organs. Radiosurgery has proved effective in local control and long-term PFS in patients with oligometastases [6,34,35]. Although most stage IV lung cancer was considered a widespread disease, stable disease or only progression in the initial site without new metastasis were noted in 50-65% of patients after effective chemotherapy at a 9-month follow-up consultation [7].…”

A prospective pilot study of curative‐intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions

“…23 Surgery and/or radiation was used. Metastases were confined to 1 organ, and most patients (n 5 14) had brain metastases.…”

The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: Does palliative thoracic radiotherapy have a useful role?

“…For patients with stage IV synchronous NSCLC and SMBA, adjuvant chemotherapy deserves consideration since the risk of micrometastatic disease exists. Recently, Khan et al [26] reported the outcomes of 23 patients presenting with oligometastatic (1 or 2 sites) NSCLC, good performance status and limited weight loss who were managed by aggressive local, regional and systemic treatment (a departure from the accepted practice of treating NSCLC patients with extrathoracic neoplastic spread with palliative therapy only). Their observation of a 22% long-term (>36 months) survival rate suggests that there may be a favorable subset of patients who could benefit from aggressive (a combination of treatments) rather than palliative therapy.…”